
Opinion|Videos|August 30, 2024
Insights on Conjugate Pneumococcal Vaccines
The vaccination experts analyze the impact of currently approved pneumococcal vaccines on otitis media prevention and compare the newer conjugate vaccines (PCV15 and PCV20) to their predecessors in terms of strain coverage and clinical efficacy.
Advertisement
Episodes in this series

- What effect do currently approved pneumococcal vaccines have on preventing otitis media?
- How do the newer conjugate vaccines (PCV15 and PCV20) compare to their predecessors in terms of strain coverage and clinical efficacy?
- What are your considerations for selecting between conjugate vaccines for adult patients who are vaccine-naïve?
- When would you use PCV20 instead of PCV15 and vice versa?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Etuvetidigene Autotemcel, First Gene Therapy for Wiskott-Aldrich Syndrome
2
Experts Weigh In on GLP-1 Agonist Use in Pediatric Patients with Obesity
3
How Next-Generation CDK Inhibitors Are Redefining Post–CDK4/6 Therapy in HR+/HER2– Metastatic Breast Cancer
4
Automation and Standardization Take Center Stage in Health System’s Centralized IV Compounding Strategy
5

















































































































































































































